RAPP vs NKTR

Analysts rate Rapport Therapeutics, Inc.

Common Stock (RAPP) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Rapport Therapeutics, Inc.

Common Stock (RAPP) delivered a total return of +92. 0%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: RAPP returned +92. 0% versus NKTR's -59. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Rapport Therapeutics, Inc.

Common Stock (RAPP) is the lower-risk stock at 1. 55β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 19% more volatile than RAPP relative to the S&P 500. On balance sheet safety, Rapport Therapeutics, Inc. Common Stock (RAPP) carries a lower debt/equity ratio of 2% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Rapport Therapeutics, Inc.

Common Stock grew EPS 24. 3% year-over-year, compared to -12. 1% for Nektar Therapeutics. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nektar Therapeutics (NKTR) is the more profitable company, earning -297.

1% net margin versus -536. 4% for Rapport Therapeutics, Inc. Common Stock — meaning it keeps -297. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTR leads at -236. 8% versus -611. 0% for RAPP. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Rapport Therapeutics, Inc.

Common Stock (RAPP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RAPP: +92. 0%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.